Mesenchymal stromal cell delivery of full-length tumor necrosis factor-related apoptosis-inducing ligand is superior to soluble type for cancer therapy

Cytotherapy

Volumn 17, Issue 7, 2015, Pages 885-896

  Yuan, ZhengQiang ^a   Kolluri, Krishna K ^a   Sage, Elizabeth K ^a   Gowers, Kate H C ^a   Janes, Sam M ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

Apoptosis; Cancer; Mesenchymal stromal cell; TRAIL; Tumor

Indexed keywords

ANTINEOPLASTIC AGENT; FULL LENGTH HUMAN TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; LENTIVIRUS VECTOR; RECOMBINANT TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; UNCLASSIFIED DRUG; TNFSF10 PROTEIN, HUMAN; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND;

ADULT; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER CELL LINE; CELL BASED GENE THERAPY; CELL DIFFERENTIATION; CELL PROLIFERATION; CELL SURFACE; CONTROLLED STUDY; DRUG FORMULATION; DRUG MECHANISM; DRUG RESISTANCE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; MESENCHYMAL STROMA CELL; PHENOTYPE; PRIORITY JOURNAL; VIRAL GENE DELIVERY SYSTEM; BIOLOGICAL THERAPY; CYTOLOGY; GENETIC TRANSDUCTION; GENETICS; METABOLISM; NEOPLASMS; PHYSIOLOGY; PROCEDURES; SECRETION (PROCESS); TUMOR CELL LINE;

APOPTOSIS; CELL LINE, TUMOR; CELL PROLIFERATION; CELL- AND TISSUE-BASED THERAPY; HUMANS; MESENCHYMAL STROMAL CELLS; NEOPLASMS; TNF-RELATED APOPTOSIS-INDUCING LIGAND; TRANSDUCTION, GENETIC;

EID: 84944197204     PISSN: 14653249     EISSN: 14772566     Source Type: Journal    
DOI: 10.1016/j.jcyt.2015.03.603     Document Type: Article

References (60)

1. Wiley S.R., Schooley K., Smolak P.J., Din W.S., Huang C.P., Nicholl J.K., et al. Identification and characterization of a new member of the TNF family that induces apoptosis. Immunity 1995, 3:673-682.
2. Pitti R.M., Marsters S.A., Ruppert S., Donahue C.J., Moore A., Ashkenazi A. Induction of apoptosis by Apo-2 ligand, a new member of the tumor necrosis factor cytokine family. J Biol Chem 1996, 271:12687-12690.
3. Lemke J., von Karstedt S., Abd El Hay M., Conti A., Arce F., Montinaro A., et al. Selective CDK9 inhibition overcomes TRAIL resistance by concomitant suppression of cFlip and Mcl-1. Cell Death Differ 2014, 21:491-502.
4. Walczak H., Miller R.E., Ariail K., Gliniak B., Griffith T.S., Kubin M., et al. Tumoricidal activity of tumor necrosis factor-related apoptosis-inducing ligand in vivo. Nat Med 1999, 5:157-163.
5. Ashkenazi A., Pai R.C., Fong S., Leung S., Lawrence D.A., Marsters S.A., et al. Safety and antitumor activity of recombinant soluble Apo2 ligand. J Clin Invest 1999, 104:155-162.
6. Kim C.Y., Jeong M., Mushiake H., Kim B.M., Kim W.B., Ko J.P., et al. Cancer gene therapy using a novel secretable trimeric TRAIL. Gene Ther 2006, 13:330-338.
7. Hotte S.J., Hirte H.W., Chen E.X., Siu L.L., Le L.H., Corey A., et al. A phase 1 study of mapatumumab (fully human monoclonal antibody to TRAIL-R1) in patients with advanced solid malignancies. Clin Cancer Res 2008, 14:3450-3455.
8. Greco F.A., Bonomi P., Crawford J., Kelly K., Oh Y., Halpern W., et al. Phase 2 study of mapatumumab, a fully human agonistic monoclonal antibody which targets and activates the TRAIL receptor-1, in patients with advanced non-small cell lung cancer. Lung Cancer 2008, 61:82-90.
9. Micheau O., Shirley S., Dufour F. Death receptors as targets in cancer. Br J Pharmacol 2013, 169:1723-1744.
10. Loebinger M.R., Eddaoudi A., Davies D., Janes S.M. Mesenchymal Stem Cell Delivery of TRAIL Can Eliminate Metastatic Cancer. Cancer Res 2009, 69:4134-4142.
11. Mohr A., Lyons M., Deedigan L., Harte T., Shaw G., Howard L., et al. Mesenchymal stem cells expressing TRAIL lead to tumour growth inhibition in an experimental lung cancer model. J Cell Mol Med 2008, 12:2628-2643.
12. Kim S.M., Lim J.Y., Park S.I., Jeong C.H., Oh J.H., Jeong M., et al. Gene therapy using TRAIL-secreting human umbilical cord blood-derived mesenchymal stem cells against intracranial glioma. Cancer Res 2008, 68:9614-9623.
13. Sage E.K., Kolluri K.K., McNulty K., Lourenco Sda S., Kalber T.L., Ordidge K.L., et al. Systemic but not topical TRAIL-expressing mesenchymal stem cells reduce tumour growth in malignant mesothelioma. Thorax 2014, 69:638-647.
14. Ho I.A., Lam P.Y. Signaling molecules and pathways involved in MSC tumor tropism. Histol Histopathol 2013, 28:1427-1438.
15. Yang Z.S., Tang X.J., Guo X.R., Zou D.D., Sun X.Y., Feng J.B., et al. Cancer cell-oriented migration of mesenchymal stem cells engineered with an anticancer gene (PTEN): an imaging demonstration. Onco Targets Ther 2014, 7:441-446.
16. Xu M.H., Gao X., Luo D., Zhou X.D., Xiong W., Liu G.X. EMT and acquisition of stem cell-like properties are involved in spontaneous formation of tumorigenic hybrids between lung cancer and bone marrow-derived mesenchymal stem cells. PLoS One 2014, 9:e87893.
17. Wang H., Chen X. Imaging mesenchymal stem cell migration and the implications for stem cell-based cancer therapies. Future Oncol 2008, 4:623-628.
18. Kolluri K.K., Laurent G.J., Janes S.M. Mesenchymal Stem Cells as Vectors for Lung Cancer Therapy. Respiration 2013, 85:443-451.
19. Studeny M., Marini F.C., Dembinski J.L., Zompetta C., Cabreira-Hansen M., Bekele B.N., et al. Mesenchymal stem cells: potential precursors for tumor stroma and targeted-delivery vehicles for anticancer agents. J Natl Cancer Inst 2004, 96:1593-1603.
20. Xin H., Kanehira M., Mizuguchi H., Hayakawa T., Kikuchi T., Nukiwa T., et al. Targeted delivery of CX3CL1 to multiple lung tumors by mesenchymal stem cells. Stem Cells 2007, 25:1618-1626.
21. Khakoo A.Y., Pati S., Anderson S.A., Reid W., Elshal M.F., Rovira, et al. Human mesenchymal stem cells exert potent antitumorigenic effects in a model of Kaposi's sarcoma. J Exp Med 2006, 203:1235-1247.
22. Menon L.G., Picinich S., Koneru R., Gao H., Lin S.Y., Koneru M., et al. Differential gene expression associated with migration of mesenchymal stem cells to conditioned medium from tumor cells or bone marrow cells. Stem Cells 2007, 25:520-528.
23. Kosztowski T., Zaidi H.A., Quinones-Hinojosa A. Applications of neural and mesenchymal stem cells in the treatment of gliomas. Expert Rev Anticancer Ther 2009, 9:597-612.
24. Komarova S., Kawakami Y., Stoff-Khalili M.A., Curiel D.T., Pereboeva L. Mesenchymal progenitor cells as cellular vehicles for delivery of oncolytic adenoviruses. Mol Cancer Ther 2006, 5:755-766.
25. Nakamizo A., Marini F., Amano T., Khan A., Studeny M., Gumin J., et al. Human bone marrow-derived mesenchymal stem cells in the treatment of gliomas. Cancer Res 2005, 65:3307-3318.
26. Yu R., Deedigan L., Albarenque S.M., Mohr A., Zwacka R.M. Delivery of sTRAIL variants by MSCs in combination with cytotoxic drug treatment leads to p53-independent enhanced antitumor effects. Cell Death Dis 2013, 4:e503.
27. Mohr A., Albarenque S.M., Deedigan L., Yu R., Reidy M., Fulda S., et al. Targeting of XIAP combined with systemic mesenchymal stem cell-mediated delivery of sTRAIL ligand inhibits metastatic growth of pancreatic carcinoma cells. Stem Cells 2010, 28:2109-2120.
28. Santilli G., Almarza E., Brendel C., Choi U., Beilin C., Blundell M.P., et al. Biochemical correction of X-CGD by a novel chimeric promoter regulating high levels of transgene expression in myeloid cells. Mol Ther 2011, 19:122-132.
29. Boshart M., Weber F., Jahn G., Dorsch-Hasler K., Fleckenstein B., Schaffner W. A very strong enhancer is located upstream of an immediate early gene of human cytomegalovirus. Cell 1985, 41:521-530.
30. Suzuki K., Hiroaki H., Kohda D., Tanaka T. An isoleucine zipper peptide forms a native-like triple stranded coiled coil in solution. Protein Eng 1998, 11:1051-1055.
31. Coloma M.J., Hastings A., Wims L.A., Morrison S.L. Novel vectors for the expression of antibody molecules using variable regions generated by polymerase chain reaction. J Immunol Methods 1992, 152:89-104.
32. Qian S.W., Li X., Zhang Y.Y., Huang H.Y., Liu Y., Sun X., et al. Characterization of adipocyte differentiation from human mesenchymal stem cells in bone marrow. BMC Dev Biol 2010, 10:47.
33. Wang Y.K., Yu X., Cohen D.M., Wozniak M.A., Yang M.T., Gao L., et al. Bone morphogenetic protein-2-induced signaling and osteogenesis is regulated by cell shape, RhoA/ROCK, and cytoskeletal tension. Stem Cells Dev 2012, 21:1176-1186.
34. Curtis K.M., Gomez L.A., Rios C., Garbayo E., Raval A.P., Perez-Pinzon M.A., et al. EF1alpha and RPL13a represent normalization genes suitable for RT-qPCR analysis of bone marrow derived mesenchymal stem cells. BMC Mol Biol 2010, 11:61.
35. Livak K.J., Schmittgen T.D. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 2001, 25:402-408.
36. Monleon I., Martinez-Lorenzo M.J., Monteagudo L., Lasierra P., Taules M., Iturralde M., et al. Differential secretion of Fas ligand- or APO2 ligand/TNF-related apoptosis-inducing ligand-carrying microvesicles during activation-induced death of human T cells. J Immunol 2001, 167:6736-6744.
37. Kischkel F.C., Lawrence D.A., Chuntharapai A., Schow P., Kim K.J., Ashkenazi A. Apo2L/TRAIL-dependent recruitment of endogenous FADD and caspase-8 to death receptors 4 and 5. Immunity 2000, 12:611-620.
38. Barde I., Zanta-Boussif M.A., Paisant S., Leboeuf M., Rameau P., Delenda C., et al. Efficient control of gene expression in the hematopoietic system using a single Tet-on inducible lentiviral vector. Mol Ther 2006, 13:382-390.
39. Chen X., Lin X., Zhao J., Shi W., Zhang H., Wang Y., et al. A tumor-selective biotherapy with prolonged impact on established metastases based on cytokine gene-engineered MSCs. Mol Ther 2008, 16:749-756.
40. Gao P., Ding Q., Wu Z., Jiang H., Fang Z. Therapeutic potential of human mesenchymal stem cells producing IL-12 in a mouse xenograft model of renal cell carcinoma. Cancer Lett 2010, 290:157-166.
41. Kidd S., Caldwell L., Dietrich M., Samudio I., Spaeth E.L., Watson K., et al. Mesenchymal stromal cells alone or expressing interferon-beta suppress pancreatic tumors in vivo, an effect countered by anti-inflammatory treatment (vol. 12, pg 615, 2010). Cytotherapy 2011, 13. 498.
42. Studeny M., Marini F.C., Champlin R.E., Zompetta C., Fidler I.J., AndreeffM. Bone marrow-derived mesenchymal stem cells as vehicles for interferon-beta delivery into tumors. Cancer Res 2002, 62:3603-3608.
43. Ren C., Kumar S., Chanda D., Kallman L., Chen J., Mountz J.D., et al. Cancer gene therapy using mesenchymal stem cells expressing interferon-beta in a mouse prostate cancer lung metastasis model. Gene Ther 2008, 15:1446-1453.
44. Hakkarainen T., Sarkioja M., Lehenkari P., Miettinen S., Ylikomi T., Suuronen R., et al. Human mesenchymal stem cells lack tumor tropism but enhance the antitumor activity of oncolytic adenoviruses in orthotopic lung and breast tumors. Hum Gene Ther 2007, 18:627-641.
45. Uchibori R., Okada T., Ito T., Urabe M., Mizukami H., Kume A., et al. Retroviral vector-producing mesenchymal stem cells for targeted suicide cancer gene therapy. J Gene Med 2009, 11:373-381.
46. Kucerova L., Matuskova M., Pastorakova A., Tyciakova S., Jakubikova J., Bohovic R., et al. Cytosine deaminase expressing human mesenchymal stem cells mediated tumour regression in melanoma bearing mice. J Gene Med 2008, 10:1071-1082.
47. Lee R.H., Yoon N., Reneau J.C., Prockop D.J. Preactivation of human MSCs with TNF-alpha enhances tumor-suppressive activity. Cell Stem Cell 2012, 11:825-835.
48. Holler N., Tardivel A., Kovacsovics-Bankowski M., Hertig S., Gaide O., Martinon F., et al. Two adjacent trimeric Fas ligands are required for Fas signaling and formation of a death-inducing signaling complex. Mol Cell Biol 2003, 23:1428-1440.
49. Stenqvist A.C., Nagaeva O., Baranov V., Mincheva-Nilsson L. Exosomes secreted by human placenta carry functional Fas ligand and TRAIL molecules and convey apoptosis in activated immune cells, suggesting exosome-mediated immune privilege of the fetus. J Immunol 2013, 191:5515-5523.
50. Kim M.H., Billiar T.R., Seol D.W. The secretable form of trimeric TRAIL, a potent inducer of apoptosis. Biochem Biophys Res Commun 2004, 321:930-935.
51. Graves J.D., Kordich J.J., Huang T.H., Piasecki J., Bush T.L., Sullivan T., et al. Apo2L/TRAIL and the death receptor 5 agonist antibody AMG 655 cooperate to promote receptor clustering and antitumor activity. Cancer Cell 2014, 26:177-189.
52. Tuthill M.H., Montinaro A., Zinngrebe J., Prieske K., Draber P., Prieske S., et al. TRAIL-R2-specific antibodies and recombinant TRAIL can synergise to kill cancer cells. Oncogene 2014.
53. Nesterov A., Nikrad M., Johnson T., Kraft A.S. Oncogenic Ras sensitizes normal human cells to tumor necrosis factor-alpha-related apoptosis-inducing ligand-induced apoptosis. Cancer Res 2004, 64:3922-3927.
54. Nieminen A.I., Partanen J.I., Hau A., Klefstrom J. c-Myc primed mitochondria determine cellular sensitivity to TRAIL-induced apoptosis. EMBO J 2007, 26:1055-1067.
55. Jeong M., Kwon Y.S., Park S.H., Kim C.Y., Jeun S.S., Song K.W., et al. Possible novel therapy for malignant gliomas with secretable trimeric TRAIL. PLoS One 2009, 4:e4545.
56. Chopin V., Slomianny C., Hondermarck H., Le Bourhis X. Synergistic induction of apoptosis in breast cancer cells by cotreatment with butyrate and TNF-alpha, TRAIL, or anti-Fas agonist antibody involves enhancement of death receptors' signaling and requires P21(waf1). Exp Cell Res 2004, 298:560-573.
57. Lawrence D., Shahrokh Z., Marsters S., Achilles K., Shih D., Mounho B., et al. Differential hepatocyte toxicity of recombinant Apo2L/TRAIL versions. Nat Med 2001, 7:383-385.
58. Jo M., Kim T.H., Seol D.W., Esplen J.E., Dorko K., Billiar T.R., et al. Apoptosis induced in normal human hepatocytes by tumor necrosis factor-related apoptosis-inducing ligand. Nat Med 2000, 6:564-567.
59. Herbst R.S., Eckhardt S.G., Kurzrock R., Ebbinghaus S., O'Dwyer P.J., Gordon M.S., et al. Phase I dose-escalation study of recombinant human Apo2L/TRAIL, a dual proapoptotic receptor agonist, in patients with advanced cancer. J Clin Oncol 2010, 28:2839-2846.
60. Pan Y., Xu R., Peach M., Huang C.P., Branstetter D., Novotny W., et al. Evaluation of pharmacodynamic biomarkers in a Phase 1a trial of dulanermin (rhApo2L/TRAIL) in patients with advanced tumours. Br J Cancer 2011, 105:1830-1838.